The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 17, 2017

Filed:

May. 02, 2016
Applicant:

Lyotropic Therapeutics, Inc., Ashland, VA (US);

Inventors:

David Anderson, Ashland, VA (US);

Benjamin G. Cameransi, Jr., Georgetown, SC (US);

Vincent M. Conklin, Richmond, VA (US);

Assignee:

Lyotropic Therapeutics, Inc., Ashland, VA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/14 (2006.01); A61K 9/00 (2006.01); A61K 31/415 (2006.01); A61K 31/4178 (2006.01); A61K 9/127 (2006.01); A61K 47/10 (2017.01); A61K 47/18 (2017.01); A61K 9/10 (2006.01); A61K 9/16 (2006.01); A61K 31/4166 (2006.01); C07D 233/80 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4178 (2013.01); A61K 9/0019 (2013.01); A61K 9/10 (2013.01); A61K 9/1274 (2013.01); A61K 9/1623 (2013.01); A61K 9/1635 (2013.01); A61K 9/1652 (2013.01); A61K 47/10 (2013.01); A61K 47/18 (2013.01); A61K 31/4166 (2013.01); C07D 233/80 (2013.01);
Abstract

Provided are low-volume, safe for injection formulations of dantrolene yielding significant advantages over the currently approved and marketed dantrolene for malignant hyperthermia (MH) threatening anesthetic crisis. Once dantrolene can be made immediately available to patients triggered of MH, the anesthesiologist will be able to focus exclusively on the management of the patient's physiologic status in this complex and evolving crisis, not on the laborious and time consuming reconstitution process of the rescue agent. The low volume, safe for injection formulations of dantrolene have significant advantages over currently used approaches to the prevention and treatment of pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations of altered blood flow, including those incurred during surgical procedures involving CPB or related procedures, as well as those incurred during non-normothermic episodes caused iatrogenically or by disease.


Find Patent Forward Citations

Loading…